Ocugen Provides Business Update and Third Quarter 2021 Financial Results
November 09, 2021 07:30 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Emergency Use Authorization application filed with the U.S. FDA for the COVID-19 vaccine candidate, COVAXIN™ (BBV152), for children aged 2 – 18...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) to Treat Inherited Retinal Degeneration
November 08, 2021 09:24 ET
|
Ocugen
MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2021 09:42 ET
|
Ocugen
MALVERN, Pa., Oct. 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2021 16:52 ET
|
Ocugen
MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
September 07, 2021 17:22 ET
|
Ocugen
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2021 16:34 ET
|
Ocugen
MALVERN, Pa., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
OCGN FINAL DEADLINE TODAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN
August 17, 2021 09:19 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021...
DEADLINE ALERT for OCGN, HMPT, TEDU, and ATHA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
August 16, 2021 11:40 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Los Angeles -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – OCGN
August 11, 2021 19:47 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and...
DEADLINE ALERT for OCGN, HMPT, TEDU, and ATHA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
August 09, 2021 11:30 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Aug. 09, 2021 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...